Patents Assigned to SUMITOMO PHARMA CO., LTD.
-
Publication number: 20140045837Abstract: The present invention provides an 8-oxoadenine compound having immunomodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.Type: ApplicationFiled: October 21, 2013Publication date: February 13, 2014Applicants: AstraZeneca Aktiebolag, Dainippon Sumitomo Pharma Co., Ltd.Inventors: Ayumu Kurimoto, Kazuki Hashimoto, Yoshiaki Isobe, Stephen Brough, Ian Millichip, Hiroki Wada, Roger Bonnert, Thomas Mcinally
-
Publication number: 20140044686Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.Type: ApplicationFiled: August 15, 2013Publication date: February 13, 2014Applicants: Dainippon Sumitomo Pharma Co., Ltd., Sapporo Medical UniversityInventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi
-
Publication number: 20140031406Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.Type: ApplicationFiled: September 30, 2013Publication date: January 30, 2014Applicant: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Izumi SASAKI, Tomohiro TOYODA, Hidefumi YOSHINAGA, Itaru NATSUTANI, Yoko TAKAHASHI
-
Patent number: 8633001Abstract: A process for producing optically active succinimide derivatives as key intermediates of (3R)-2?-(4-bromo-2-fluorobenzyl)spiro{pyrrolidine-3,4?(1?H)-pyrrolo[1,2-a]pyrazine}-1?,2,3?,5(2?H)-tetraone, which comprises the following reaction steps.Type: GrantFiled: February 5, 2010Date of Patent: January 21, 2014Assignees: Dainippon Sumitomo Pharma Co., Ltd., Kyowa Hakko Bio Co., Ltd.Inventors: Masaji Kasai, Shinji Kita, Tadashi Ogawa, Hideaki Tokai
-
Publication number: 20140018416Abstract: A compound represented by formula (1), or a pharmaceutically acceptable salt thereof is effective as a therapeutic agent or a prophylactic agent for a corneal disease or sensory nerve damage due to corneal surgery, and as a regeneration accelerator for corneal sensory nerves: wherein R1 represents a hydrogen atom or a carboxyl group, R2 represents a hydrogen atom or a hydroxy group, R3 represents a hydrogen atom or a carboxyl group, and R4 represents a hydrogen atom or a hydroxy group.Type: ApplicationFiled: February 23, 2012Publication date: January 16, 2014Applicants: DAINIPPON SUMITOMO PHARMA CO., LTD, KEIO UNIVERSITYInventors: Hideyuki Okano, Kazuo Tsubota, Shigeto Shimmura, Masahiro Omoto, Akiyoshi Kishino, Miho Maeda
-
Patent number: 8628957Abstract: The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.Type: GrantFiled: February 10, 2012Date of Patent: January 14, 2014Assignees: Dainippon Sumitomo Pharma Co., Ltd., National Cancer CenterInventors: Takumi Teratani, Takahiro Ochiya
-
Patent number: 8597895Abstract: The invention provides an antibody that specifically binds to (a) a protein having an amino acid sequence depicted in SEQ ID NO:16 or 32 or (b) a protein which has an amino acid sequence of (a), wherein one to several amino acids are deleted, substituted, or added, and which is specifically expressed in an ES cell.Type: GrantFiled: March 19, 2012Date of Patent: December 3, 2013Assignees: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Shinya Yamanaka, Eiko Kaiho
-
Patent number: 8598370Abstract: The present invention provides a process for producing Droxidopa or a pharmaceutically acceptable salt thereof comprising a step of reacting threo-N-phthaloyl-3-(3,4-dihydroxyphenyl)-L-serine represented by the formula (1) with methylamine, whereby a process for producing threo-3-(3,4-dihydroxyphenyl)-L-serine (common name: Droxidopa), which is useful as an agent for treatment of peripheral orthostatic hypotension or an agent for treatment of Parkinson's disease, with high production efficiency and without requiring troublesome operations.Type: GrantFiled: June 29, 2010Date of Patent: December 3, 2013Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toshikazu Yagi, Koji Koyama, Masanori Itoh
-
Patent number: 8591955Abstract: The present invention provides an orally rapidly-disintegrating tablet comprising at least two particles. Regarding medicaments with unpleasant taste, the present invention provides a tablet comprising such medicament having a suitable hardness so that the tablet can be handled without any difficulty in the period from the formulation of the tablet to the administration thereof (in particular, a tablet which can maintain the hardness thereof when it is stored under a humidified condition); a small size; no unpleasant taste; a pleasant feeling in a mouth after administration; and an excellent disintegration character in the oral cavity and an excellent dissolution character in the gastrointestinal tract.Type: GrantFiled: August 11, 2010Date of Patent: November 26, 2013Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventor: Keiichi Fujiwara
-
Patent number: 8591879Abstract: The present invention provides a novel adenovirus vector for which inflammation during the in vivo administration thereof is alleviated by inhibiting the induction of expression of an adenovirus gene by a foreign promoter inserted into the adenovirus genome, and a method for producing the vector, a cell line for use in the production of the recombinant adenovirus vector, or a gene therapy method using the recombinant adenovirus vector.Type: GrantFiled: June 3, 2011Date of Patent: November 26, 2013Assignee: Dainippon Sumitomo Pharma Co., LtdInventors: Michio Nakai, Kazuo Komiya, Masashi Murata, Naoki Tohdoh, Izumu Saito
-
Patent number: 8591913Abstract: A pharmaceutical composition including, as an active ingredient, one of the following proteins (I) and (II): (I) an apoptosis inhibitor of macrophage; and (II) a protein which consists of an amino acid sequence having deletion, substitution, or addition of one or more amino acids in an amino acid sequence of the apoptosis inhibitor of macrophage and having homology to the amino acid sequence of the apoptosis inhibitor of macrophage, and has a function of inhibiting the differentiation of preadipocytes to mature adipocytes and/or a function of inducing lipolysis in the mature adipocytes.Type: GrantFiled: January 23, 2012Date of Patent: November 26, 2013Assignees: Toru Miyazaki, Dainippon Sumitomo Pharma Co., Ltd.Inventor: Toru Miyazaki
-
Patent number: 8586737Abstract: The present invention relates to a novel process for preparing quaternary ammonium salt derivatives.Type: GrantFiled: April 26, 2011Date of Patent: November 19, 2013Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Nobuyuki AE, Yuji Fujiwara
-
Patent number: 8575308Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.Type: GrantFiled: March 22, 2011Date of Patent: November 5, 2013Assignees: International Institute of Cancer Immunology, Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toshio Nishihara, Masashi Gotoh
-
Patent number: 8575180Abstract: The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.Type: GrantFiled: July 20, 2011Date of Patent: November 5, 2013Assignees: AstraZeneca Aktiebolag, Dainippon Sumitomo Pharma Co., Ltd.Inventors: Ayumu Kurimoto, Kazuki Hashimoto, Yoshiaki Isobe, Stephen Brough, Ian Millichip, Hiroki Wada, Roger Bonnert, Thomas Mcinally
-
Publication number: 20130289277Abstract: The present invention relates to a medicament comprising lurasidone or a pharmaceutically acceptable acid addition salt thereof for treating pervasive developmental disorders and a method of the treatment thereof.Type: ApplicationFiled: March 14, 2013Publication date: October 31, 2013Applicant: Dainippon Sumitomo Pharma Co., Ltd.Inventor: Tsuyoshi TSUJIMURA
-
Patent number: 8569353Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.Type: GrantFiled: July 14, 2011Date of Patent: October 29, 2013Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Izumi Sasaki, Tomohiro Toyoda, Hidefumi Yoshinaga, Itaru Natsutani, Yoko Takahashi
-
Publication number: 20130280732Abstract: The present invention provides an agent for determining Alzheimer's disease, comprising an anti-S38AA antibody, a method of determining Alzheimer's disease in a test animal, comprising detecting an S38AA fragment in a sample collected from said animal, and a method of screening for a substance that treats or prevents Alzheimer's disease, comprising contacting a test substance with a cell permitting measurement of production of a S38AA fragment, measuring the production amount of the S38AA fragment in the cell, and comparing the production amount with that of the S38AA fragment in a control cell free of contact with the test substance, and selecting a test substance that down-regulates the production amount of the S38AA fragment as a substance capable of treating or preventing Alzheimer's disease, based on the comparison results.Type: ApplicationFiled: December 28, 2011Publication date: October 24, 2013Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.Inventors: Masakazu Hashimoto, Hiroyuki Nakagawa, Mikio Aoki, Lars O. Tjernberg, Bengt Winblad
-
Patent number: 8557998Abstract: Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R1 represents a hydrogen atom or a methyl group; R2 is a group bound in a p- or m-position relative to a methylene group and represents a chlorine atom bound in a p-position, a bromine atom bound in a p-position, a methyl group bound in a p-position, a chlorine atom bound in a m-position or a bromine atom bound to in a m-position; X represents a methylene or an oxygen atom; and n represents an integer of 1 to 3.Type: GrantFiled: June 20, 2012Date of Patent: October 15, 2013Assignee: Dainippon Sumitomo Pharma Co., LtdInventor: Tomohiro Toyoda
-
Patent number: 8552000Abstract: A therapeutic/preventive agent for cognitive dysfunctions, which comprises as an active ingredient an imide derivative of the following formula [1]: wherein Z is a group of the formula [2]: D is a group of —(CH2)p-A-(CH2)q—; G is ?N—, —CH—, etc.; and Ar is an aromatic heterocyclic group, etc.Type: GrantFiled: February 29, 2012Date of Patent: October 8, 2013Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Yukihiro Ohno, Takeo Ishiyama
-
Patent number: 8541544Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.Type: GrantFiled: October 27, 2009Date of Patent: September 24, 2013Assignees: Dainippon Sumitomo Pharma Co., Ltd., Sapporo Medical UniversityInventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi